A protein called PACS-2 plays a big role in transporting the enzyme ADAM17 into patient cells, making this an appealing target for cancer drug developers, according to a team at the University of Copenhagen.
Alzheimer's has long been one of the most contentious fields in drug development. As one drug after the next failed in late-stage clinical studies, drug developers have been moving further and further upstream in the disease process to see if they can more effectively blunt the progress of this disease in early-stage patients.
In a recent study, scientists at The Scripps Research Institute have characterized new antibodies that protect against the ebolavirus' sinister relative--the Marburg virus.
Scientists at the Salk Institute and Sanford Burnham Prebys Medical Discovery Institute designed a small molecule inhibitor to block the first step in the autophagy process, demonstrating its potential for starving tumor growth.
Early on in the course of colorectal cancer, a protein known as Dishevelled-associating protein with high levels of leucine residues, or Daple, acts as a brake on the cancer. But the same protein, a key coordinator for tissue produced by most cells, becomes a cancer accelerator for late-stage patients, spurring metastasis and speeding the death of patients.
Investigators at University College London have identified a compound that targets unusual knots frequently found inside faulty genes and determined that it proved effective in shrinking pancreatic tumors in mice. And while they say this particular compound isn't suitable for clinical testing, the team believes that another member of this family of medications could prove fruitful in fighting one of the most lethal cancers in the book.
Researchers at Purdue University say they have identified molecules that can shut down a key enzyme needed by the Middle East respiratory syndrome, or MERS, virus.
Dr. Matthias Eder of the German Cancer Research Center has been working on a new molecule that targets prostate-specific membrane antigen, a protein that clusters on the surface of prostate cancer cells.
Just about a year after Bristol-Myers Squibb and Allied Minds got together to create Allied-Bristol Life Sciences with plans to collaborate on new biotech spinoffs, the joint venture has inlicensed research from Harvard University that may eventually lead to new drugs for fibrotic and autoimmune diseases.
Following up on what's billed as the largest epidemiological study ever done on Parkinson's disease, a group of scientists at Aarhus University in Denmark say they have determined that the neurological ailment begins in the gut and then spreads through the body by way of the vagus nerve.
Francesc Rabanal, a professor in the Department of Organic Chemistry of the University of Barcelona, has spearheaded work on a new prototype compound that he says shows clear activity against both Gram-negative and Gram-positive bacteria.
John Herr's lab at the University of Virginia made the cover of the scientific journal Biology of Reproduction with new work on finding a male contraceptive.
Researchers led by Yu-Hua Tseng at Joslin Diabetes Center and Harvard Medical School say they have created cell lines of human brown and white fat precursor cells that should help drug investigators working in the field.
Mutations in the TCF12 gene, which plays a big role in developing brains in the embryo, has been tied to an aggressive form of brain cancer.
Harvard synthetic biologist Pamela Silver has led a successful effort to transplant the "wiring" used for circadian rhythm into a common species of bacteria, a process that could one day help regulate the body's natural rhythm or even aid in drug delivery and development.
Dalantercept (ACE-041) is owned by Acceleron and is currently in early clinical trials for liver and kidney carcinomas. More recently, though, researchers at Lund University demonstrated that it could block the activin receptor-like 1 (ALK1) pathway, suggesting it may also slow metastasis in aggressive breast cancer.
A team of scientists from The Scripps Research Institute led by Dr. Patrick Griffin has observed for the first time that a novel compound may help promote bone formation in patients afflicted with bone loss.
Investigators will be making the trek to Washington later this month to make the case for a new study that will explore the impact that metformin has on aging. And in the process, they'll be testing regulators' attitudes about an emerging field in drug development.
Following the theory that Type 2 diabetes is triggered by inflammation, a group of researchers at the German Cancer Research Center concluded that turning off the enzyme Kit prevented a cascade of metabolically linked pathogenic processes.
Researchers have known for years just how sketchy preclinical biomedical research can be. Reports on research projects that can capture headlines around the world are also not infrequently impossible to reproduce. And now a new study has attempted to put a dollar figure on the amount of research produced in the U.S. each year that can't be reproduced.